EFNS guidelines for the diagnosis and management of Alzheimer's disease

. 2010 Oct ; 17 (10) : 1236-48.

Jazyk angličtina Země Velká Británie, Anglie Médium print

Typ dokumentu časopisecké články, směrnice pro lékařskou praxi

Perzistentní odkaz   https://www.medvik.cz/link/pmid20831773

BACKGROUND AND OBJECTIVES: In 2008 a task force was set up to develop a revision of the European Federation of the Neurological Societies (EFNS) guideline for the diagnosis and management of Alzheimer's disease (AD) and other disorders associated with dementia, published in early 2007. The aim of this revised international guideline was to present a peer-reviewed evidence-based statement for the guidance of practice for clinical neurologists, geriatricians, psychiatrists, and other specialist physicians responsible for the care of patients with AD. Mild cognitive impairment and non-Alzheimer dementias are not included in this guideline. METHODS: The task force working group reviewed evidence from original research articles, meta-analysis, and systematic reviews, published before May 2009. The evidence was classified and consensus recommendations graded (A, B, or C) according to the EFNS guidance. Where there was a lack of evidence, but clear consensus, good practice points were provided. RESULTS: The recommendations for clinical diagnosis, blood tests, neuropsychology, neuroimaging, electroencephalography, cerebrospinal fluid (CSF) analysis, genetic testing, disclosure of diagnosis, treatment of AD, behavioural and psychological symptoms in dementia, legal issues, counselling and support for caregivers were all revised as compared with the previous EFNS guideline. CONCLUSION: A number of new recommendations and good practice points are made, namely in CSF, neuropsychology, neuroimaging and reviewing non-evidence based therapies. The assessment, interpretation, and treatment of symptoms, disability, needs, and caregiver stress during the course of AD require the contribution of many different professionals. These professionals should adhere to these guideline to improve the diagnosis and management of AD.

Citace poskytuje Crossref.org

Nejnovějších 20 citací...

Zobrazit více v
Medvik | PubMed

Alzheimer's disease and synapse Loss: What can we learn from induced pluripotent stem Cells?

. 2023 Dec ; 54 () : 105-118. [epub] 20230114

Contribution of Memory Tests to Early Identification of Conversion from Amnestic Mild Cognitive Impairment to Dementia

. 2022 ; 88 (4) : 1397-1409.

The Concentration of Memantine in the Cerebrospinal Fluid of Alzheimer's Disease Patients and Its Consequence to Oxidative Stress Biomarkers

. 2019 ; 10 () : 943. [epub] 20190828

Dementia care in the Danube Region. A multi-national expert survey

. 2019 ; 15 () : 2503-2511. [epub] 20190829

Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey

. 2019 Aug 22 ; 11 (1) : 74. [epub] 20190822

Concentration of Donepezil in the Cerebrospinal Fluid of AD Patients: Evaluation of Dosage Sufficiency in Standard Treatment Strategy

. 2017 Jan ; 31 (1) : 162-168. [epub] 20161007

Alzheimer's disease and its treatment costs: case study in the Czech Republic

. 2015 ; 11 () : 2349-54. [epub] 20150911

Blood markers of oxidative stress in Alzheimer's disease

. 2012 Oct ; 16 (10) : 2291-300.

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...